Long non-coding RNAs as emerging regulators of miRNAs and epigenetics in diabetes-related chronic kidney disease

References

• Alghamdi, T., et al., 2018. Histone H3 serine 10 phosphorylation facilitates endothelial activation in diabetic kidney disease. Diabetes, 67 (1), 492-P.
   Google Scholar
• Alicic, R.Z., et al., 2017. Diabetic kidney disease: challenges, progress, and possibilities. Clinical journal of the American Society of Nephrology, 12 (12), 2032–2045.
   PubMed Web of Science ®Google Scholar
• Alnajjar, F.A., et al., 2021. The expression and function of metastases associated lung adenocarcinoma transcript-1 long non-coding RNA in subchondral bone and osteoblasts from patients with osteoarthritis. Cells, 10 (4), 786.
   PubMed Web of Science ®Google Scholar
• Alvarez, M.L., et al., 2013. Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy. PLoS one, 8 (10), e77468.
   PubMed Web of Science ®Google Scholar
• Amodio, N., et al., 2018. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. Journal of hematology & oncology, 11 (1), 63.
   PubMed Web of Science ®Google Scholar
• Anders, H.J., et al., 2016. Nephron protection in diabetic kidney disease. The New England journal of medicine, 375 (21), 2096–2098.
   PubMed Web of Science ®Google Scholar
• Begolli, R., et al., 2019. LncRNAs as chromatin regulators in cancer: from molecular function to clinical potential. Cancers, 11 (10), 1524.
   PubMed Web of Science ®Google Scholar
• Bijkerk, R., et al., 2019. Long non-coding RNAs rian and miat mediate myofibroblast formation in kidney fibrosis. Frontiers in pharmacology, 10, 215.
   PubMed Web of Science ®Google Scholar
• Bose, D.A., et al., 2017. RNA binding to CBP stimulates histone acetylation and transcription. Cell, 168 (1-2), 135–149.
   PubMed Web of Science ®Google Scholar
• Briggs, T.A., et al., 2016. Temple syndrome as a result of isolated hypomethylation of the 14q32 imprinted DLK1/MEG3 region. American journal of medical genetics. Part A, 170A (1), 170–175.
   PubMedGoogle Scholar
• Cai, R. and Jiang, J., 2020. LncRNA ANRIL silencing alleviates high glucose-induced inflammation, oxidative stress, and apoptosis via upregulation of MME in podocytes. Inflammation, 43 (6), 2147–2155.
   PubMed Web of Science ®Google Scholar
• Cantile, M., et al., 2021. Functional interaction among lncRNA HOTAIR and microRNAs in cancer and other human diseases. Cancers, 13 (3), 570.
   PubMed Web of Science ®Google Scholar
• Cao, L., et al., 2020. LncRNA PVT1 suppresses the progression of renal fibrosis via inactivation of TGF-β signaling pathway. Drug design, development and therapy, 14, 3547–3557.
   PubMed Web of Science ®Google Scholar
• Cao, X. and Fan, Q.-L., 2020. LncRNA MIR503HG promotes high-glucose-induced proximal tubular cell apoptosis by targeting miR-503-5p/Bcl-2 pathway. Diabetes, metabolic syndrome and obesity: targets and therapy, 13, 4507–4517.
   PubMed Web of Science ®Google Scholar
• Castro, N.E., et al., 2014. Transforming growth factor β1 (TGF-β1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells. Journal of biological chemistry, 289 (42), 29001–29013.
   PubMed Web of Science ®Google Scholar
• Chakraborty, C., et al., 2021. Therapeutic advances of miRNAs: a preclinical and clinical update. Journal of advanced research, 28, 127–138.
   PubMed Web of Science ®Google Scholar
• Chen, H., et al., 2020a. LncRNA Gm12840 mediates WISP1 to regulate ischemia-reperfusion-induced renal fibrosis by sponging miR-677-5p. Epigenomics, 12 (24), 2205–2218.
   PubMed Web of Science ®Google Scholar
• Chen, J., et al., 2020b. LncRNA RPSAP52 regulates miR-423-5p/GSTM1 axis to suppress hypoxia-induced renal proximal tubular epithelial cell apoptosis. Archives of physiology and biochemistry, 1–5.
   Web of Science ®Google Scholar
• Chen, L., et al., 2021. LncRNA TUG1 regulates the development of ischemia-reperfusion mediated acute kidney injury through miR-494-3p/E-cadherin axis. Journal of inflammation, 18 (1), 12.
   Google Scholar
• Chen, P.-Y., et al., 2012. FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell reports, 2 (6), 1684–1696.
   PubMed Web of Science ®Google Scholar
• Chen, W., et al., 2019. The topological key lncRNA H2k2 from the ceRNA network promotes mesangial cell proliferation in diabetic nephropathy via the miR-449a/b/Trim11/Mek signaling pathway. FASEB journal, 33 (10), 11492–11506.
   PubMed Web of Science ®Google Scholar
• Chung, A. and Lan, H.Y., 2015. MicroRNAs in renal fibrosis. Frontiers in physiology, 6, 50.
   PubMed Web of Science ®Google Scholar
• Coellar, J.D., et al., 2021. Long noncoding RNAs and their therapeutic promise in diabetic nephropathy. Nephron, 145 (4), 404–414.
   PubMed Web of Science ®Google Scholar
• Conserva, F., et al., 2019. Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of kidney fibrosis in diabetic nephropathy. Scientific reports, 9 (1), 11357.
   PubMedGoogle Scholar
• Cox, A., et al., 2020. The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. Clinical & translational oncology, 22 (9), 1524–1531.
   PubMed Web of Science ®Google Scholar
• Dias, S., et al., 2017. MicroRNA expression varies according to glucose tolerance, measurement platform, and biological source. BioMed research international, 2017, 1080157.
   PubMed Web of Science ®Google Scholar
• Dieter, C., et al., 2021. The impact of lncRNAs in diabetes mellitus: a systematic review and in silico analyses. Frontiers in endocrinology, 12, 602597.
   PubMedGoogle Scholar
• Ding, H., et al., 2020. LncRNA MALAT1 induces the dysfunction of β cells via reducing the histone acetylation of the PDX-1 promoter in type 1 diabetes. Experimental and molecular pathology, 114, 104432.
   PubMed Web of Science ®Google Scholar
• Duan, L.J., et al., 2017. Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ in diabetic nephropathy. Biochemical and biophysical research communications, 484 (3), 598–604.
   PubMed Web of Science ®Google Scholar
• Engreitz, J.M., et al., 2016. Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nature reviews. molecular cell biology, 17 (12), 756–770.
   PubMed Web of Science ®Google Scholar
• Fan, W., et al., 2020. LINC00162 participates in the pathogenesis of diabetic nephropathy via modulating the miR-383/HDAC9 signalling pathway. Artificial cells, nanomedicine, and biotechnology, 48 (1), 1047–1054.
   PubMed Web of Science ®Google Scholar
• Feng, Y., et al., 2018. Dysregulation of lncRNAs GM5524 and GM15645 involved in high‑glucose‑induced podocyte apoptosis and autophagy in diabetic nephropathy. Molecular medicine reports, 18 (4), 3657–3664.
   PubMed Web of Science ®Google Scholar
• Fontecha-Barriuso, M., et al., 2018. Targeting epigenetic DNA and histone modifications to treat kidney disease. Nephrology, dialysis, transplantation, 33 (11), 1875–1886.
   PubMed Web of Science ®Google Scholar
• Fourdinier, O., et al., 2019. Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Scientific reports, 9 (1), 4477.
   PubMedGoogle Scholar
• Gaikwad, A.B., et al., 2010. Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. The American journal of pathology, 176 (3), 1079–1083.
   PubMed Web of Science ®Google Scholar
• Gao, Y., et al., 2017. Long non-coding RNA ASncmtRNA-2 is upregulated in diabetic kidneys and high glucose-treated mesangial cells. Experimental and therapeutic medicine, 13 (2), 581–587.
   PubMed Web of Science ®Google Scholar
• Gareev, I., et al., 2020. The current state of MiRNAs as biomarkers and therapeutic tools. Clinical and experimental medicine, 20 (3), 349–359.
   PubMed Web of Science ®Google Scholar
• Ge, X., et al., 2019a. Long noncoding RNA GAS5 inhibits cell proliferation and fibrosis in diabetic nephropathy by sponging miR-221 and modulating SIRT1 expression. Aging, 11 (20), 8745–8759.
   PubMedGoogle Scholar
• Ge, Y., et al., 2019b. lncRNA NR_038323 suppresses renal fibrosis in diabetic nephropathy by targeting the miR-324-3p/DUSP1 axis. Molecular therapy. Nucleic acids, 17, 741–753.
   PubMedGoogle Scholar
• Gholaminejad, A., et al., 2018. Identification of candidate microRNA biomarkers in renal fibrosis: a meta-analysis of profiling studies. Biomarkers, 23 (8), 713–724.
   PubMed Web of Science ®Google Scholar
• Ghosh, A.K., et al., 2012. Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT. Cellular signalling, 24 (5), 1031–1036.
   PubMed Web of Science ®Google Scholar
• Gu, Y.-Y., et al., 2020. Non-coding RNAs as biomarkers and therapeutic targets for diabetic kidney disease. Frontiers in pharmacology, 11, 583528.
   PubMed Web of Science ®Google Scholar
• He, X., et al., 2017. LncRNAs: key players and novel insights into diabetes mellitus. Oncotarget, 8 (41), 71325–71341.
   PubMedGoogle Scholar
• He, Y., et al., 2013. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie, 95 (7), 1355–1359.
   PubMed Web of Science ®Google Scholar
• Jiang, X. and Ning, Q., 2020. The mechanism of lncRNA H19 in fibrosis and its potential as novel therapeutic target. Mechanisms of ageing and development, 188, 111243.
   PubMed Web of Science ®Google Scholar
• Jiang, Z.J., et al., 2019. Influence of lncRNA HOTAIR on acute kidney injury in sepsis rats through regulating miR-34a/Bcl-2 pathway. European review for medical and pharmacological science, 23 (8), 3512–3519.
   PubMed Web of Science ®Google Scholar
• Jie, R., et al., 2020. LncRNA KCNQ1OT1 affects cell proliferation, apoptosis and fibrosis through regulating miR-18b-5p/SORBS2 axis and NF-ĸB pathway in diabetic nephropathy. Diabetology & metabolic syndrome, 12 (1), 77.
   PubMed Web of Science ®Google Scholar
• Jung, H.J., et al., 2020. Potential roles of long noncoding RNAs as therapeutic targets in renal fibrosis. International journal of molecular sciences, 21 (8), 2698.
   Web of Science ®Google Scholar
• Kale, A., et al., 2021. Epigenetic and non-epigenetic regulation of Klotho in kidney disease. Life sciences, 264, 118644.
   PubMed Web of Science ®Google Scholar
• Kanasaki, K., et al., 2014. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes, 63 (6), 2120–2131.
   PubMed Web of Science ®Google Scholar
• Kato, M., et al., 2016. An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy. Nature communications, 7 (1), 12864.
   PubMedGoogle Scholar
• Kim, M. and Zhang, X., 2019. The profiling and role of miRNAs in diabetes mellitus. Journal of diabetes and clinical research, 1 (1), 5–23.
   PubMedGoogle Scholar
• Kölling, M., et al., 2017. Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice. Molecular therapy, 25 (1), 165–180.
   PubMed Web of Science ®Google Scholar
• Kong, W., et al., 2008. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Molecular and cellular biology, 28 (22), 6773–6784.
   PubMed Web of Science ®Google Scholar
• Kopp, J.B., et al., 2020. Podocytopathies. Nature reviews. Disease primers, 6 (1), 68.
   PubMed Web of Science ®Google Scholar
• Kumarswamy, R., et al., 2012. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arteriosclerosis, thrombosis, and vascular biology, 32 (2), 361–369.
   PubMed Web of Science ®Google Scholar
• Lecamwasam, A., et al., 2021. DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease. Nephrology dialysis transplantation, 36 (11), 2027–2038.
   PubMed Web of Science ®Google Scholar
• Leung, A., et al., 2019. Linking diabetic vascular complications with LncRNAs. Vascular pharmacology, 114, 139–144.
   PubMed Web of Science ®Google Scholar
• Li, A., et al., 2018a. LincRNA 1700020I14Rik alleviates cell proliferation and fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1α signaling. Cell death & disease, 9 (5), 461.
   PubMedGoogle Scholar
• Li, C., et al., 2021. Competing endogenous RNA network analysis explores the key lncRNAs, miRNAs, and mRNAs in type 1 diabetes. BMC medical genomics, 14 (1), 35.
   PubMed Web of Science ®Google Scholar
• Li, J., et al., 2020a. Endothelial FGFR1 (fibroblast growth factor receptor 1) deficiency contributes differential fibrogenic effects in kidney and heart of diabetic mice. Hypertension, 76 (6), 1935–1944.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2016. Histone acetylation and its modifiers in the pathogenesis of diabetic nephropathy. Journal of diabetes research, 2016, 4065382.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2017. A novel interplay between HOTAIR and DNA methylation in osteosarcoma cells indicates a new therapeutic strategy. Journal of cancer research and clinical oncology, 143 (11), 2189–2200.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2019. Long noncoding RNA MALAT1 mediates high glucose-induced glomerular endothelial cell injury by epigenetically inhibiting klotho via methyltransferase G9a. IUBMB life, 71 (7), 873–881.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2020b. LNCRNA CDKN2B-AS1 regulates mesangial cell proliferation and extracellular matrix accumulation via miR-424-5p/HMGA2 axis. Biomedicine & pharmacotherapy, 121, 109622.
   PubMed Web of Science ®Google Scholar
• Li, Z., et al., 2018b. LncRNA LINC00968 accelerates the proliferation and fibrosis of diabetic nephropathy by epigenetically repressing p21 via recruiting EZH2. Biochemical and biophysical research communications, 504 (2), 499–504.
   PubMed Web of Science ®Google Scholar
• Liu, B., et al., 2020a. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. Cell death & disease, 11 (5), 384.
   PubMed Web of Science ®Google Scholar
• Liu, D.-W., et al., 2019. Silencing of long noncoding RNA PVT1 inhibits podocyte damage and apoptosis in diabetic nephropathy by upregulating FOXA1. Experimental & molecular medicine, 51 (8), 1–15.
   Google Scholar
• Liu, J., et al., 2021a. SNHG15 knockdown inhibits diabetic nephropathy progression in pediatric patients by regulating the miR-141/ICAM-1 axis in vitro. Bioscience reports, 41 (2), BSR20204099.
   PubMed Web of Science ®Google Scholar
• Liu, Q., et al., 2020b. Mesenchymal stem cells modified with angiotensin-converting enzyme 2 are superior for amelioration of glomerular fibrosis in diabetic nephropathy. Diabetes research and clinical practice, 162, 108093.
   PubMed Web of Science ®Google Scholar
• Liu, R., et al., 2021b. Circular RNA HIPK3 exacerbates diabetic nephropathy and promotes proliferation by sponging miR-185. Gene, 765, 145065.
   PubMed Web of Science ®Google Scholar
• Loganathan, T.S., et al., 2020. Interactions among non-coding RNAs in diabetic nephropathy. Frontiers in pharmacology, 11, 191.
   PubMed Web of Science ®Google Scholar
• Lv, W., et al., 2018. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiological genomics, 50 (1), 20–34.
   PubMed Web of Science ®Google Scholar
• Ma, F., et al., 2011. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nature immunology, 12 (9), 861–869.
   PubMed Web of Science ®Google Scholar
• Malmuthuge, N. and Guan, L.L., 2021. Noncoding RNAs: regulatory molecules of host–microbiome crosstalk. Trends in microbiology, 29 (8), 713–724.
   PubMed Web of Science ®Google Scholar
• Min, X.Q. and Xie, Y., 2020. LncRNA CASC2 alleviates the progression of diabetic nephropathy by regulating the miR-144/SOCS2 signalling axis. Kidney and blood pressure research, 45 (6), 837–849.
   PubMed Web of Science ®Google Scholar
• Mitra, A., et al., 2018. Circular RNAs and competing endogenous RNA (ceRNA) networks. Translational cancer research, 7 (5), S624–S628.
   PubMedGoogle Scholar
• Nagai, T., et al., 2014. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. BioMed research international, 2014, 696475.
   PubMed Web of Science ®Google Scholar
• Nanus, D.E., et al., 2020. Regulation of the inflammatory synovial fibroblast phenotype by metastasis-associated lung adenocarcinoma transcript 1 long noncoding RNA in obese patients with osteoarthritis. Arthritis & rheumatology, 72 (4), 609–619.
   PubMed Web of Science ®Google Scholar
• Park, S., et al., 2018. Urinary and blood microRNA-126 and -770 are potential noninvasive biomarker candidates for diabetic nephropathy: a meta-analysis. Cellular physiology and biochemistry, 46 (4), 1331–1340.
   PubMedGoogle Scholar
• Pearson, M.J. and Jones, S.W., 2016. Review: long noncoding RNAs in the regulation of inflammatory pathways in rheumatoid arthritis and osteoarthritis. Arthritis & rheumatology, 68 (11), 2575–2583.
   PubMed Web of Science ®Google Scholar
• Pearson, M.J., et al., 2016. Long intergenic noncoding RNAs mediate the human chondrocyte inflammatory response and are differentially expressed in osteoarthritis cartilage. Arthritis & rheumatology, 68 (4), 845–856.
   PubMed Web of Science ®Google Scholar
• Peng, Y. and Croce, C.M., 2016. The role of microRNAs in human cancer. Signal transduction and targeted therapy, 1 (1), 15004.
   PubMedGoogle Scholar
• Qin, B. and Cao, X., 2021. LncRNA PVT1 regulates high glucose-induced viability, oxidative stress, fibrosis, and inflammation in diabetic nephropathy via miR-325-3p/Snail1 axis. Diabetes, metabolic syndrome and obesity: targets and therapy, 14, 1741–1750.
   PubMed Web of Science ®Google Scholar
• Ren, J. and Crowley, S.D., 2020. Twist1: a double-edged sword in kidney diseases. Kidney diseases, 6 (4), 247–257.
   PubMed Web of Science ®Google Scholar
• Roulé, T., et al., 2020. The lncRNA modulates the epigenetic reprogramming of the marneral cluster in response to ABA. bioRxiv, 2020.2008.2010.236562.
   Google Scholar
• Sankrityayan, H., et al., 2019. Diabetic nephropathy: the regulatory interplay between epigenetics and microRNAs. Pharmacological research, 141, 574–585.
   PubMed Web of Science ®Google Scholar
• Sayyed, S.G., et al., 2010. Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. Nephrology, dialysis, transplantation, 25 (6), 1811–1817.
   PubMed Web of Science ®Google Scholar
• Sharifian, R., et al., 2018. Distinct patterns of transcriptional and epigenetic alterations characterize acute and chronic kidney injury. Scientific reports, 8 (1), 17870.
   PubMedGoogle Scholar
• Sheng, L. and Zhuang, S., 2020. New insights into the role and mechanism of partial epithelial-mesenchymal transition in kidney fibrosis. Frontiers in physiology, 11, 1190.
   Web of Science ®Google Scholar
• Shi, J., et al., 2019. lncRNA ROR promotes the progression of renal cell carcinoma through the miR‑206/VEGF axis. Molecular medicine reports, 20 (4), 3782–3792.
   PubMed Web of Science ®Google Scholar
• Shi, S., et al., 2020. Knockdown of LncRNA-H19 ameliorates kidney fibrosis in diabetic mice by suppressing miR-29a-mediated endMT. Frontiers in pharmacology, 11, 586895.
   PubMed Web of Science ®Google Scholar
• Siddiqi, F.S., et al., 2016. The histone methyltransferase enzyme enhancer of Zeste homolog 2 protects against podocyte oxidative stress and renal injury in diabetes. Journal of the American Society of Nephrology, 27 (7), 2021–2034.
   PubMed Web of Science ®Google Scholar
• Srivastava, S.P., et al., 2020. Inhibition of angiotensin-converting enzyme ameliorates renal fibrosis by mitigating DPP-4 level and restoring antifibrotic microRNAs. Genes, 11 (2), 211.
   Web of Science ®Google Scholar
• Srivastava, S.P., et al., 2013. MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. BioMed research international, 2013, 125469–125469.
   PubMed Web of Science ®Google Scholar
• Srivastava, S.P., et al., 2019. MicroRNA crosstalk influences epithelial-to-mesenchymal, endothelial-to-mesenchymal, and macrophage-to-mesenchymal transitions in the kidney. Frontiers in pharmacology, 10, 904.
   PubMed Web of Science ®Google Scholar
• Srivastava, S.P., et al., 2021a. Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys. iScience, 24 (5), 102390.
   PubMed Web of Science ®Google Scholar
• Srivastava, S.P., et al., 2021b. Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy. Nature communications, 12 (1), 2368.
   PubMed Web of Science ®Google Scholar
• Srivastava, S.P., et al., 2021c. Podocyte glucocorticoid receptors are essential for glomerular endothelial cell homeostasis in diabetes mellitus. Journal of the American Heart Association, 10 (15), e019437.
   PubMed Web of Science ®Google Scholar
• Sun, P., et al., 2020. Prediction of potential associations between miRNAs and diseases based on matrix decomposition. Frontiers in genetics, 11, 598185–598185.
   PubMed Web of Science ®Google Scholar
• Sun, S.F., et al., 2018. Novel lncRNA Erbb4-IR promotes diabetic kidney injury in db/db mice by targeting miR-29b. Diabetes, 67 (4), 731–744.
   PubMed Web of Science ®Google Scholar
• Vajir, M., et al., 2019. Histone acetylation regulates natriuretic peptides and neprilysin gene expressions in diabetic cardiomyopathy and nephropathy. Current molecular pharmacology, 12 (1), 61–71.
   PubMed Web of Science ®Google Scholar
• Wallace, C., et al., 2010. The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nature genetics, 42 (1), 68–71.
   PubMed Web of Science ®Google Scholar
• Wang, G., et al., 2020. LncRNA CTBP1-AS2 alleviates high glucose-induced oxidative stress, ECM accumulation, and inflammation in diabetic nephropathy via miR-155-5p/FOXO1 axis. Biochemical and biophysical research communications, 532 (2), 308–314.
   PubMed Web of Science ®Google Scholar
• Wang, J. and Zhao, S.-M., 2021. LncRNA-antisense non-coding RNA in the INK4 locus promotes pyroptosis via miR-497/thioredoxin-interacting protein axis in diabetic nephropathy. Life sciences, 264, 118728.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2018. lncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy. Molecular therapy. nucleic acids, 12, 741–750.
   PubMedGoogle Scholar
• Wang, X., et al., 2014. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy. Kidney international, 86 (4), 712–725.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2019. LncRNA NEAT1 promotes extracellular matrix accumulation and epithelial-to-mesenchymal transition by targeting miR-27b-3p and ZEB1 in diabetic nephropathy. Journal of cellular physiology, 234 (8), 12926–12933.
   PubMed Web of Science ®Google Scholar
• Wijesinghe, S.N., et al., 2021. Involvements of long noncoding RNAs in obesity-associated inflammatory diseases. Obesity reviews, 22 (4), e13156.
   PubMed Web of Science ®Google Scholar
• Xia, H., et al., 2010. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochemical and biophysical research communications, 391 (1), 535–541.
   PubMed Web of Science ®Google Scholar
• Xiao, H., et al., 2020. Competing endogenous RNA regulation in hematologic malignancies. Clinica chimica acta, 509, 108–116.
   PubMed Web of Science ®Google Scholar
• Xu, X.H., et al., 2017. Resveratrol transcriptionally regulates miRNA-18a-5p expression ameliorating diabetic nephropathy via increasing autophagy. European review for medical and pharmacol sciences, 21 (21), 4952–4965.
   PubMed Web of Science ®Google Scholar
• Yang, J., et al., 2019. Silencing of long noncoding RNA XIST protects against renal interstitial fibrosis in diabetic nephropathy via microRNA-93-5p-mediated inhibition of CDKN1A. American journal of physiology. Renal physiology, 317 (5), F1350–F1358.
   PubMed Web of Science ®Google Scholar
• Yarahmadi, A., et al., 2020. MicroRNAs in diabetic nephropathy: from molecular mechanisms to new therapeutic targets of treatment. Biochemical pharmacology, 189, 114301.
   PubMed Web of Science ®Google Scholar
• Yi, H., et al., 2017. LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy. Cell death & disease, 8 (2), e2583.
   PubMedGoogle Scholar
• Yin, D., et al., 2018. Long noncoding RNA AFAP1-AS1 predicts a poor prognosis and regulates non-small cell lung cancer cell proliferation by epigenetically repressing p21 expression. Molecular cancer, 17 (1), 92.
   PubMedGoogle Scholar
• Yu, Y., et al., 2021. PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms. BMC nephrology, 22 (1), 27.
   PubMed Web of Science ®Google Scholar
• Zang, X., et al., 2020. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression. Cell death & disease, 11 (4), 215.
   PubMed Web of Science ®Google Scholar
• Zhang, H., et al., 2021. LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy. Life sciences, 266, 118794.
   PubMed Web of Science ®Google Scholar
• Zhang, J., et al., 2018a. LincRNA-p21 sponges miR-18b to promote the progression of diabetic nephropathy. American journal of translational research, 10 (5), 1481–1489.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2017a. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney international, 92 (1), 140–153.
   PubMed Web of Science ®Google Scholar
• Zhang, P., et al., 2019a. Long non-coding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3. Cell death & disease, 10 (7), 526.
   PubMedGoogle Scholar
• Zhang, R., et al., 2020. MicroRNA‑199a‑3p suppresses high glucose‑induced apoptosis and inflammation by regulating the IKKβ/NF‑κB signaling pathway in renal tubular epithelial cells. International journal of molecular medicine, 46 (6), 2161–2171.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2017b. The long noncoding RNA Malat1: its physiological and pathophysiological functions. RNA biology, 14 (12), 1705–1714.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2018b. The long noncoding RNA 150Rik promotes mesangial cell proliferation via miR-451/IGF1R/p38 MAPK signaling in diabetic nephropathy. Cellular physiology and biochemistry, 51 (3), 1410–1428.
   PubMedGoogle Scholar
• Zhang, Y., et al., 2019b. LncRNA SOX2OT alleviates the high glucose-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis. Experimental and molecular pathology, 110, 104283.
   PubMed Web of Science ®Google Scholar
• Zhao, H., et al., 2019. microRNAs in chronic kidney disease. Clinica chimica acta, 491, 59–65.
   PubMed Web of Science ®Google Scholar
• Zhao, J.-T., et al., 2020. LINC00174 is an oncogenic lncRNA of hepatocellular carcinoma and regulates miR-320/S100A10 axis. Cell biochemistry and function, 38 (7), 859–869.].
   PubMed Web of Science ®Google Scholar
• Zhao, M., et al., 2018. MALAT1: a long non-coding RNA highly associated with human cancers. Oncology letters, 16 (1), 19–26.
   PubMed Web of Science ®Google Scholar
• Zhou, J., et al., 2013. A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene, 527 (2), 456–461.
   PubMed Web of Science ®Google Scholar
• Zhou, J., et al., 2021. Hyperoside ameliorates diabetic nephropathy induced by STZ via targeting the miR-499-5p/APC axis. Journal of pharmacological sciences, 146 (1), 10–20.
   PubMed Web of Science ®Google Scholar
• Zhou, L., et al., 2015. Long non-coding MIAT mediates high glucose-induced renal tubular epithelial injury. Biochemical and biophysical research communications, 468 (4), 726–732.
   PubMed Web of Science ®Google Scholar
• Zhou, L., et al., 2018. Long non-coding RNA MALAT1 interacts with transcription factor Foxo1 to regulate SIRT1 transcription in high glucose-induced HK-2 cells injury. Biochemical and biophysical research communications, 503 (2), 849–855.
   PubMed Web of Science ®Google Scholar
• Zhou, Y., et al., 2020. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2. Journal of biochemistry, 167 (3), 295–301.
   PubMed Web of Science ®Google Scholar
• Zhu, X.-J., et al., 2019. Long non-coding RNA Hottip modulates high-glucose-induced inflammation and ECM accumulation through miR-455-3p/WNT2B in mouse mesangial cells. International journal of clinical and experimental pathology, 12 (7), 2435–2445.
   PubMed Web of Science ®Google Scholar